This cohort has several notable limitations, most importantly that it used rwPFS (OS is impacted by later line therapies), it reflects real-world treatments often guided by PD-L1 IHC, and several included tumor types do not have both anti-PD-(L)1 monotherapy and combination chemotherapy indicated/recommended in the same treatment line. This evidence concerns the gene CD274 and neoplasm.